Source ID: C10
Original URL: https://pubmed.ncbi.nlm.nih.gov/41125110/
Source date (attachment preserved): 2025-10-19
Data date (attachment preserved): 
Checked at: 2026-10-07T18:42:25+08:00
Timezone: Asia/Taipei
Retrieval mode: public_url_web_tool
Read level: PubMed 原始論文公開摘要及書目；未讀期刊全文
Access result: 正常取得原 URL 公開摘要
Original raw artifact SHA256: null

LOCATORS (actual reading positions):
PubMed PMID 41125110；Abstract / Methods，L296–298；Findings，L299–300（turn135view0）
書目 Epub 2025 Oct 19，L244

MINIMUM VERBATIM EXCERPT (only this block is source prose):
Grade 3 or higher treatment-related adverse events occurred in 80% of patients receiving iza-bren and 62% of those receiving chemotherapy.

EXTRACTED FACTUAL FIELDS (not a reconstructed quotation):
[
  {
    "locator": "Abstract Methods L296–298",
    "trial": "BL-B01D1-303 / NCT06118333",
    "phase": 3,
    "centres": 55,
    "country": "China",
    "population": "復發或轉移鼻咽癌；至少二線全身化療，含至少一個含鉑療程，且接受過 PD-1 或 PD-L1 抑制劑",
    "comparator": "chemotherapy",
    "analysis": "first planned interim analysis"
  },
  {
    "locator": "Abstract Findings L299",
    "endpoint": "masked independent central review ORR",
    "unit": "percent",
    "iza_bren": 54.6,
    "chemotherapy": 27.0,
    "iza_bren_95ci": [
      45.2,
      63.8
    ],
    "chemotherapy_95ci": [
      19.1,
      36.0
    ],
    "N_total": 386,
    "N_iza_bren": 191,
    "N_chemotherapy": 195
  },
  {
    "locator": "Abstract Findings L300",
    "endpoint": "grade >=3 treatment-related adverse events",
    "unit": "percent",
    "iza_bren": 80,
    "chemotherapy": 62,
    "OS_maturity": "immature at data cutoff",
    "trial_data_cutoff": null
  }
]

SCOPE / PRECISE GAP (reviewer description, not source prose):
支持限摘要可見之 NPC 設計、ORR 及 TRAE；不以此來源核 TNBC、ESCC 或完整論文。摘要未明列確切 data cutoff，保持未知。

Web refs: turn111view1, turn135view0